NK cell cytotoxicity in Chediak-Higashi syndrome (CHS) is strongly impaired as lytic granules are not released upon NK-target cell contact, contributing to several defects typical of this severe immunodeficiency. Correction of NI(cell defects in CHS should improve the outcome of hematopoietic stem-cell transplantation, proposed as therapy.We investigated NK cell functions in a CHS patient before and after cord-blood transplantation, and the ability of in vitro IL-2 treatment to restore them.Before the transplant, the strong defect in NK cell-mediated natural and antibody-dependent cytotoxicity, as well as in IFN-gamma production, could be restored up to normal levels by in vitro IL-2 treatment. This cytokine also caused the appearance of smaller lysosomal granules and their orientation towards the NK-target cell contact area, thus suggesting that IL-2 had a more general capacity to restore NK cell effector functions. Moreover after the transplant, although the successful engraftment, NK cell cytotoxicity resulted still partially impaired at one year, almost normal at ten years and, anyhow, fully recovered by in vitro IL-2 treatment.Taken together, our results indicate that IL-2 had a wide capacity to restore NK cell effector functions, being able to reverse the altered cytotoxic activity, lytic granule pattern, and cytokine production observed in the CHS patient. (C) 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Cifaldi, L., Pinto, R.m., Rana, I., Caniglia, M., Angioni, A., Petrocchi, S., et al. (2016). NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2. IMMUNOLOGY LETTERS, 180, 46-53 [10.1016/j.imlet.2016.10.009].

NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2

Cifaldi, Loredana
;
Petrocchi, Stefano;Cancrini, Caterina;Palumbo, Giuseppe;Rossi, Paolo;
2016

Abstract

NK cell cytotoxicity in Chediak-Higashi syndrome (CHS) is strongly impaired as lytic granules are not released upon NK-target cell contact, contributing to several defects typical of this severe immunodeficiency. Correction of NI(cell defects in CHS should improve the outcome of hematopoietic stem-cell transplantation, proposed as therapy.We investigated NK cell functions in a CHS patient before and after cord-blood transplantation, and the ability of in vitro IL-2 treatment to restore them.Before the transplant, the strong defect in NK cell-mediated natural and antibody-dependent cytotoxicity, as well as in IFN-gamma production, could be restored up to normal levels by in vitro IL-2 treatment. This cytokine also caused the appearance of smaller lysosomal granules and their orientation towards the NK-target cell contact area, thus suggesting that IL-2 had a more general capacity to restore NK cell effector functions. Moreover after the transplant, although the successful engraftment, NK cell cytotoxicity resulted still partially impaired at one year, almost normal at ten years and, anyhow, fully recovered by in vitro IL-2 treatment.Taken together, our results indicate that IL-2 had a wide capacity to restore NK cell effector functions, being able to reverse the altered cytotoxic activity, lytic granule pattern, and cytokine production observed in the CHS patient. (C) 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/04
English
Cellular immunology
Cord blood transplantation
Immunodeficiency
Interleukin 2
NK cells
Antibody-Dependent Cell Cytotoxicity
Cell Line
Chediak-Higashi Syndrome
Cytotoxicity, Immunologic
Fetal Blood
Hematopoietic Stem Cell Transplantation
Humans
Infant
Interleukin-2
Killer Cells, Natural
Lymphocyte Activation
Male
Cifaldi, L., Pinto, R.m., Rana, I., Caniglia, M., Angioni, A., Petrocchi, S., et al. (2016). NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2. IMMUNOLOGY LETTERS, 180, 46-53 [10.1016/j.imlet.2016.10.009].
Cifaldi, L; Pinto, Rm; Rana, I; Caniglia, M; Angioni, A; Petrocchi, S; Cancrini, C; Cursi, L; Palumbo, G; Zingoni, A; Gismondi, A; Rossi, P; Santoni, A; Cerboni, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/305396
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact